CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
CBLL filed a notice that the Josef Parvizi Trust plans to sell 1,300 shares of its common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 26000.00. The issuer had 37,095,690 common shares outstanding.
The 1,300 shares were originally acquired on 08/29/2014 as pre‑IPO compensation from the issuer. Over the past three months, the Josef Parvizi Trust has already sold three blocks of 25,000 common shares each, generating gross proceeds of 506,467.06, 538,650.34, and 573,453.07.
Ceribell, Inc. President, CEO and director Xingjuan (Jane) Chao reported a series of planned stock transactions on February 4, 2026 under a Rule 10b5-1 trading plan adopted on September 12, 2025. She sold 14,000 shares of common stock at a weighted average price of $20.16, with individual sale prices ranging from $19.87 to $20.61.
On the same date she exercised stock options for 1,446 shares and 23,554 shares at an exercise price of $4.70 per share and sold the same numbers of shares at a weighted average price of $20.16. Following these transactions, she beneficially owned 727,248 shares of Ceribell common stock directly and 369,088 shares indirectly through the ACP 2021 Trust, where she is a co‑trustee and disclaims beneficial ownership except to the extent of her pecuniary interest.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 3,928,666.28 shares of Ceribell Inc common stock, representing 10.6% of the class as of 12/31/2025. The filing identifies both FMR LLC and Abigail P. Johnson as reporting persons with sole dispositive power over these shares and no shared voting or dispositive power.
The shares are reported as held in the ordinary course of business and not for the purpose of changing or influencing control of Ceribell. One or more other persons have rights to dividends or sale proceeds, but no single other person has more than five percent of the outstanding common stock.
Ceribell, Inc. officer David Foehr reported option exercises and share sales in company stock. On February 3, 2026, he exercised options to buy 3,403 and 2,153 shares at $4.70 per share and then sold the same amounts at $20.00 per share under a prearranged Rule 10b5-1 trading plan.
After these transactions, Foehr directly owned 18,900 shares of Ceribell common stock and held stock options covering 59,598 and 57,445 shares. The option grant vests 25% on May 31, 2023, with the remainder vesting in 36 equal monthly installments.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported planned option exercises and share sales in company stock. On February 2, 2026, he exercised several stock options at prices of $2.24 and $4.70 per share and sold the resulting common shares at weighted average prices around $20.57, all under a pre‑established Rule 10b5‑1 trading plan adopted on May 28, 2025.
Following these transactions, Woo directly beneficially owned 167,617 shares of Ceribell common stock, which includes 300 shares acquired through the company’s employee stock purchase plan on January 30, 2026. He also continues to hold multiple stock options that remain outstanding, some of which are fully vested and currently exercisable and others that continue to vest monthly from April 1, 2023.
CBLL shareholder Xingjuan Chao has filed a Form 144 to sell 39,000 shares of common stock, with an aggregate market value of $799,890, through Fidelity Brokerage Services on NASDAQ around February 4, 2026. The notice shows these shares coming from stock option exercises dated April 30, 2018 and February 4, 2026.
Over the prior three months, the same shareholder reported CBLL common stock sales of 50,000 shares on November 21, 2025, 25,000 shares on December 1, 2025, 25,000 shares on December 4, 2025, and 79,000 shares on January 5, 2026, with disclosed gross proceeds for each transaction.
CBLL insider David J. Foehr has filed a Form 144 notice to sell common stock. The filing covers a planned sale of 5,556 CBLL common shares through Fidelity Brokerage Services, with an aggregate market value of 111,120.00, on or about 02/03/2026 on NASDAQ.
The filing states that 37,095,690 CBLL shares were outstanding. The shares to be sold were acquired via stock options granted on 06/23/2022 and paid for in cash on 02/03/2026. Over the past three months, Foehr sold 5,265 shares for 88,609.95 on 12/03/2025 and 5,556 shares for 125,565.60 on 01/05/2026.
Raymond Woo filed a notice to sell 11,112 common shares of CBLL under Rule 144. The planned sale, through Fidelity Brokerage Services on NASDAQ, has an aggregate market value of $231,129.60 and is targeted for approximately February 2, 2026.
The shares were acquired by exercising stock options on February 2, 2026 that were originally granted on July 7, 2021 and February 16, 2023, for 1,472 and 9,640 shares respectively, paid in cash. Over the past three months, Woo has sold 11,112 CBLL common shares on each of November 11, 2025, December 1, 2025, and January 2, 2026, for gross proceeds of $136,496.56, $184,424.30, and $235,228.09.
Josef Parvizi Trust, an entity associated with Ceribell director Josef Parvizi, sold 25,000 shares of Ceribell common stock on January 15, 2026 at a weighted average price of $22.94 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2025, meaning the trades were pre-arranged rather than discretionary on the trade date. After the sale, the Josef Parvizi Trust held 747,652 shares, while the Innovation ACP Trust held 907,911 shares and the ACP 2021 Trust held 369,088 shares, all reported as indirectly owned, with beneficial ownership disclaimed except to the extent of pecuniary interest.
A shareholder has filed a notice of proposed sale under Rule 144 for 25,000 shares of common stock, to be sold through Fidelity Brokerage Services LLC on NASDAQ around 01/15/2026. The filing lists an aggregate market value of $573,453.07 for these shares and states that there are 37,095,690 common shares outstanding.
The 25,000 shares to be sold were originally acquired as pre-IPO shares from the issuer on 08/29/2014 for cash. The document also reports that the Josef Parvizi Trust sold 25,000 common shares on 12/08/2025 for gross proceeds of $506,467.06 and another 25,000 common shares on 12/15/2025 for gross proceeds of $538,650.34.